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Use of Self-Delivery siRNAs to Inhibit Gene
Expression in an Organotypic Pachyonychia
Congenita Model
Robyn P. Hickerson1, Manuel A. Flores1, Devin Leake2, Maria F. Lara3, Christopher H. Contag3,
Sancy A. Leachman4 and Roger L. Kaspar1,3
Although RNA interference offers therapeutic potential for treating skin disorders, delivery hurdles have
hampered clinical translation. We have recently demonstrated that high pressure, resulting from intradermal
injection of large liquid volumes, facilitated nucleic acid uptake by keratinocytes in mouse skin. Furthermore,
similar intradermal injections of small interfering RNA (siRNA; TD101) into pachyonychia congenita (PC) patient
foot lesions resulted in improvement. Unfortunately, the intense pain associated with hypodermic needle
administration to PC lesions precludes this as a viable delivery option for this disorder. To investigate siRNA
uptake by keratinocytes, an organotypic epidermal model, in which pre-existing endogenous gene or reporter
gene expression can be readily monitored, was used to evaluate the effectiveness of ‘‘self-delivery’’ siRNA (i.e.,
siRNA chemically modified to enhance cellular uptake). In this model system, self-delivery siRNA treatment
resulted in reduction of pre-existing fluorescent reporter gene expression under conditions in which
unmodified controls had little or no effect. Additionally, treatment of PC epidermal equivalents with self-
delivery ‘‘TD101’’ siRNA resulted in marked reduction of mutant keratin 6a mRNA with little or no effect on wild-
type expression. These results indicate that chemical modification of siRNA may overcome certain limitations to
transdermal delivery (specifically keratinocyte uptake) and may have clinical utility for inhibition of gene
expression in the skin.
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INTRODUCTION
Since the discovery that small interfering RNAs (siRNAs) can
effectively silence gene expression in a number of mammalian
systems, there has been increasing interest in developing these
inhibitors as therapeutics to treat a variety of diseases, including
those of the skin. Although siRNA-based therapeutics are
currently in clinical trials for a number of targets, including
the liver, kidney, lung, skin, and eye, as recently reviewed
(Vaishnaw et al., 2010), a number of inherent physical barrier
properties of the skin represent formidable hurdles to siRNA
delivery and progress into the clinic has been impeded.
To develop effective siRNA-based therapeutics for treat-
ment of skin disorders, it is necessary to first identify potent and
specific inhibitors and then develop effective delivery methods
for these nucleic acid inhibitors to target cells in the skin. For
the treatment of pachyonychia congenita (PC), we have
identified inhibitors that are both selective and potent
(Hickerson et al., 2008; Smith et al., 2008). The first reported
siRNA clinical trial (Phase 1b) in skin used one of these
inhibitors (TD101) to treat this rare skin disorder, and some
efficacy was noted (Leachman et al., 2008, 2010). PC is a
dominant negative skin disorder caused by mutations in the
inducible keratin genes, including KRT6A, KRT6B, KRT16, or
KRT17 genes, which often result in thickened dystrophic nails,
leukokeratosis, and acanthosis histologically with painful
blistering (Leachman et al., 2005; Smith et al., 2006).
Detailed clinical and genetic analysis of PC is reported by
Wilson et al., 2011, and will be reported by Eliason et al.
(personal communications). TD101 siRNA (also known as
K6a_513a.12 siRNA, see Hickerson et al., 2008) specifically
targets the keratin 6a (K6a) single C to A nucleotide mutation,
which results in the K6a p.Asn171Lys amino acid mutation.
Delivery of functional siRNA to skin (specifically to the
epidermal keratinocytes) involves (i) stratum corneum penetration
and (ii) keratinocyte uptake followed by incorporation into the
RNA-induced silencing complex. Although hydrodynamic in-
tradermal injection of unmodified, standard siRNA (i.e., siRNA
without the modifications that allow for ‘‘self-delivery’’) to mouse
skin resulted in target inhibition (Gonzalez-Gonzalez et al.,
2009), treatment methods that do not involve generation of
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pressure, such as topical formulations or microneedles, do not
result in target knockdown (Gonzalez-Gonzalez et al., 2010b
and unpublished data). In this study, we have evaluated keratino-
cyte uptake and demonstrate that chemically-modified self-
delivery siRNAs can inhibit target gene expression in human
organotypic epidermal cultures. These epidermal equivalents
represent a keratinocyte siRNA uptake model to evaluate
the effectiveness of modified siRNAs for their ability to inhibit
endogenous or reporter gene expression when added to the
organotypic culture medium. This allows the rapid assessment of
keratinocyte uptake of functional siRNA, bypassing the compli-
cating stratum corneum barrier.
RESULTS
Self-delivery siRNAs block reporter expression in primary
human keratinocytes
In vivo imaging of fluorescent and bioluminescent reporters
offers the opportunity to quantitatively and repeatedly
monitor siRNA-mediated effects non-invasively, allowing
spatiotemporal analyses to be performed. Use of these
reporters in human primary keratinocyte and skin equivalent
models serves to accelerate and refine the study of siRNA
delivery and the effects of these agents.
In order to take advantage of intravital fluorescence
imaging systems, human primary epidermal keratinocyte
progenitor (HPEKp) cells were transduced with two different
lentiviral reporter constructs to generate a multi-reporter cell
line expressing enhanced green fluorescent protein (EGFP)
and a fusion reporter gene (Luc2/tdTOM) comprised of a
highly modified luciferase gene (Luc2) and tandem tomato
fluorescent protein (tdTOM), as shown in Figure 1a. This
fusion construct contains the target site for an siRNA
called CBL3 (Gonzalez-Gonzalez et al., 2009). We have
previously reported that unmodified and self-delivery (Accell)
CBL3 siRNAs potently and specifically reduced reporter
gene expression in human 293FT cells and in a transgenic
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Figure 1. Specific inhibition of reporter protein in a dual fluorescent reporter human primary keratinocyte cell line using self-delivery small interfering RNAs
(siRNAs). (a) Schematic representation of the lentiviral expression plasmids used to generate the dual reporter cell line. vTD171 expresses tandem tomato
fluorescent protein (tdTOM), containing the CBL3 siRNA target site in the 30untranslated region, under the control of the human ubiquitin C promoter. vTD147
expresses enhanced green fluorescent protein (EGFP) under the control of the human phosphoglycerate kinase (PGK) promoter. (b) Human primary epidermal
keratinocyte progenitor (HPEKp) cells were transduced with vTD171 and sorted for cells expressing tdTOM. The collected cells were then transduced with
vTD147 and sorted for cells expressing EGFP. The resulting cell line was positive for both tdTOM and EGFP expression in495% of the cells. Cells were treated
24hours after seeding with 2 mM (final concentration) of the indicated siRNAs (self-delivery nonspecific control K6a_513a.12 siRNA, non-self-delivery CBL3
siRNA, and self-delivery CBL3 siRNA) and imaged 96 hours after treatment. Scale bar¼100 mm.
1038 Journal of Investigative Dermatology (2011), Volume 131
RP Hickerson et al.
Functional siRNA Delivery in a Skin Model
reporter mouse model (Gonzalez-Gonzalez et al., 2009,
2010b).
Human PEKp cells were treated with 2 mM self-delivery
CBL3 siRNA (Accell) and analyzed for reporter fluorescence
96 hours after treatment. Specific knockdown of tdTOM
expression was visualized by fluorescence microscopy
following treatment with the self-delivery CBL3 siRNA, while
as expected, treatment with controls (including non-self-
delivery CBL3) had little or no effect (Figure 1b). No relative
EGFP inhibition was observed with control or specific
siRNAs, as this construct does not contain the CBL3 siRNA
target site (see Figure 1a).
Self-delivery siRNA knocks down reporter gene expression
in skin equivalents
To evaluate the ability of self-delivery CBL3 siRNA to inhibit
target reporter gene expression in a human epidermal model,
HPEKp cells were transduced with vTD152, which contains
the EGFP coding region followed by the CBL3 siRNA target
site (Figure 2a). Epidermal equivalents prepared from EGFP-
transduced cells readily differentiate, stratify, and maintain
EGFP expression (Figure 2c). On day 12 following addition of
the differentiation medium (skin equivalents fully differentiate
by day 14; see Supplementary Figure S1 online), epidermal
equivalents were treated every other day with self-delivery
CBL3 siRNA and control siRNAs for 14 days (eight treatments
total) and repeatedly imaged for EGFP expression before each
treatment. EGFP reporter levels in epidermal equivalents
treated with self-delivery CBL3 siRNA decreased 57±5% by
day 26 relative to treatment with nonspecific control siRNA
(K6a_513a.12) and remained at that level for over a week
before beginning to return to baseline levels (Figure 2b).
Treatment with non-self-delivery CBL3 siRNA resulted in
slight inhibition of reporter signal (21±1%) that quickly
returned to baseline once treatment ceased. On day 42, a
representative epidermal equivalent from each treatment
group was sectioned and imaged for EGFP expression. Skin
equivalents treated with self-delivery CBL3 siRNA showed
decreased expression of EGFP in all epidermal strata,
including the live layers, which was not observed in the
controls (Figure 2c).
Use of patient biopsies to generate a PC disease model
In order to determine if self-delivery siRNAs selectively
inhibit mutant gene expression in a PC model, primary
keratinocytes were isolated from two non-related PC patients
harboring the K6a p.Asn171Lys mutation (IPCRR patients
no. 10 and no. 799). Self-delivery K6a_513a.12 siRNA
efficiently reduces mutant mRNA expression with little effect
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Figure 2. Self-delivery enhanced green fluorescent protein (EGFP)-specific
small interfering RNA (siRNA) inhibits reporter expression in transduced
skin equivalents. (a) Human primary epidermal keratinocyte progenitor
(HPEKp) cells were transduced with vTD152 lentivirus expressing EGFP
containing the CBL3 siRNA target site in the 30 untranslated region and
used to generate epidermal equivalents (see Materials and Methods).
(b) Assessment of self-delivery siRNA functional activity by fluorescence
imaging. The skin equivalents were allowed to mature for B2 weeks before
treatment with 2mM siRNA (unmodified nonspecific K6a_513a.12 siRNA,
non-self-delivery CBL3 siRNA, or self-delivery CBL3 siRNA; in triplicate)
every 48 hours. Skin equivalents were repeatedly imaged every 48 hours for
EGFP fluorescence. (c) Sectioning of treated skin equivalents. On day 44, one
of the three skin equivalents from each treatment group was frozen in optimal
cutting temperature compound and sectioned (10 mm). The slides were
mounted with Hydromount containing 40,6-diamidino-2-phenylindole
(DAPI) to counterstain nuclei. Sections were imaged using a fluorescence
microscope equipped with GFP and DAPI filter sets. Scale bar¼ 50mm.
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on wild-type K6a expression in monolayer tissue culture
experiments in both cell lines (data not shown). Epidermal
equivalents were prepared from primary keratinocytes
isolated from IPCRR patient no. 799. Beginning on day 4
post-differentiation, the epidermal equivalents were treated
every other day (nine treatments total; Figure 3a). Two days
following the final treatment, the equivalents were collected
and half of each was used for immunohistochemical analysis
and the remaining half for quantitative reverse transcription
PCR. As expected, immunohistochemical staining showed
expression of keratin 5 (K5) predominantly in the basal layer
and keratin 10 (K10) in the suprabasal layers, similar to skin
equivalents prepared from pooled normal HPEKp cells
(Supplementary Figure S1 online). Mutant K6a mRNA levels
were reduced 80% in epidermal equivalents treated with self-
delivery K6a_513a.12 siRNA compared with 42% reduction
of wild-type mRNA levels relative to untreated controls.
Mutant and wild-type mRNA levels remained unchanged
relative to untreated controls in epidermal equivalents treated
with control siRNAs (Figure 3b).
DISCUSSION
RNA interference has therapeutic potential for treating a
variety of disorders, including those of the skin. Skin is an
attractive target for siRNA-based therapeutics, as it is readily
accessible for localized treatment (minimizing potential
problems associated with systemic administration) and
monitoring (visually, with intravital imaging, and/or by
biopsy). The ability to design, screen and identify potent,
selective, and stable siRNAs is now relatively straightforward.
We and others have developed siRNAs that have single-
nucleotide specificity in tissue culture cells and mice
(Schwarz et al., 2006; Hickerson et al., 2008). Unfortunately
the ability to deliver these potential therapeutics to appro-
priate tissues and cells has not kept pace.
Two of the major obstacles to siRNA delivery to skin are
penetration through the stratum corneum barrier and efficient
functional siRNA uptake by keratinocytes, including incor-
poration into the RNA-induced silencing complex. The
stratum corneum barrier, composed of terminally differen-
tiated squamous cells containing a hydrophobic inter-
cellular lipid matrix, prevents efficient penetration of large
(4500Da), charged molecules (e.g., siRNA is highly anionic
and B13,000Da) that are topically administered. The
advantages and disadvantages of a number of methods to
facilitate stratum corneum penetration have been summar-
ized in a recent review (Geusens et al., 2009), including tape
stripping, ballistic delivery, microneedle application, intra-
dermal injection, sonophoresis, electroporation, jet injection,
iontophoresis, chemical enhancers, lipid-based systems, and
chemical depilation.
The methods used for efficient nucleic acid (including
siRNA) delivery across the stratum corneum barrier (e.g., by
intradermal injection or microneedles) do not necessarily
result in efficient uptake and functional activity. A number of
methods to facilitate cellular siRNA uptake in skin have been
reported. High pressure (‘‘pressure fection’’), resulting from
intradermal injection of relatively large volumes of liquid
results in enhanced delivery and expression of plasmid
constructs (Gonzalez-Gonzalez et al., 2010a) and likely
uptake of functional siRNA (Gonzalez-Gonzalez et al., 2009,
2010b) by keratinocytes in mouse skin. Electroporation has
been shown to increase membrane permeability and enhance
delivery of molecules to tissues in vivo (Heller and Heller,
2006), including siRNA in a skin xenograft mouse model
(Takei et al., 2008). Furthermore, Kigasawa et al. (2010)
showed that iontophoresis facilitates siRNA penetration
through the stratum corneum and subsequent silencing of
an endogenous gene (IL-10) in rats.
A variety of chemical methods allowing cellular uptake
has also been reported. Lipid-based formulations are highly
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Figure 3. Self-delivery K6a_513a.12 small interfering RNA (siRNA)
selectively inhibits mutant K6a mRNA expression in skin equivalents
prepared from pachyonychia congenita (PC) patient primary keratinocytes.
(a) Timeline summarizing treatment schedule. (b) Skin equivalents prepared
from patient keratinocytes were treated with 2mM self-delivery K6a_513a.12
and control siRNAs as indicated (non-self-delivery K6a_513a.12 siRNA,
unmodified enhanced green fluorescent protein (EGFP)-specific siRNA, and
self-delivery K6a_513a.12 siRNA; in triplicate). Total RNA was isolated and
mutant (Mut; p.Asn171Lys) and wild-type (WT) K6a mRNA levels were
determined by quantitative reverse transcription PCR relative to
glyceraldehyde-3-phosphate dehydrogenase mRNA levels.
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effective in vitro, and some efficacy in vivo has been
reported, as recently reviewed (Whitehead et al., 2009).
Binding of peptide transduction domains or cell penetrating
peptides non-covalently to siRNA via a double-stranded RNA
binding domain facilitates siRNA delivery, as recently
reviewed (Meade and Dowdy, 2009). Administration of these
peptide–siRNA complexes has been shown to reduce target
gene expression in a mouse xenograft brain tumor model
(Michiue et al., 2009). Modified siRNAs containing lipophilic
groups have also been shown to specifically inhibit target
gene expression without the use of carrier molecules
or transfection reagents. Alnylam Pharmaceuticals demon-
strated that conjugation of lipid and steroid groups increases
delivery efficiency both in vitro and in vivo (Lorenz et al.,
2004; Soutschek et al., 2004). More recently, Wu et al. (2009)
demonstrated that intravaginal administration of choles-
terol-conjugated siRNA allowed protection from HSV-2 in
mice. Other self-delivery siRNAs are being developed
by RXi Pharma (sd-rxRNA, http://www.rxipharma.com).
In this study, we have evaluated Accell self-delivery
siRNAs (CBL3 and K6a_513a.12) and demonstrate specific
target inhibition in epidermal skin equivalents expressing
reporter proteins or skin equivalents prepared from PC
patient-derived keratinocytes by repeated and non-invasive
imaging over the course of the experiment. Recently,
self-delivery siRNAs delivered by microneedle arrays to
transgenic reporter mice have been shown to silence target
gene expression (Gonzalez-Gonzalez et al., 2010b), suggest-
ing that this approach may have clinical utility, in which
direct, local administration is feasible. Owing to the
proprietary nature of the self-delivery siRNAs (at least for
the Dharmacon and RXi inhibitors), it is unknown if these
inhibitors are working through a similar mechanism(s)
such as conjugations of lipids or steroid moieties, as
demonstrated by Alnylam Pharmaceuticals or through a
distinct mechanism.
Although several studies have described successful deliv-
ery of siRNA to skin, improvements are likely needed for
successful translation to the clinic (for a review, see Geusens
et al., 2009). For example, although intradermal injection
delivers functional unmodified siRNA to skin keratinocytes
in mouse models (Wang et al., 2007; Hickerson et al., 2008;
Smith et al., 2008; Gonzalez-Gonzalez et al., 2009), this
delivery is likely mediated through high pressure as described
above (Gonzalez-Gonzalez et al., 2009, 2010a) and may
result in unacceptable pain levels in some indications,
especially where large areas of skin require treatment. For
example, in the recently completed Phase 1b PC clinical trial
using TD101 siRNA to target a mutant keratin 6a mRNA,
intradermal injection resulted in significant improvements in
PC symptoms; however, the pain associated with adminis-
tration to the exquisitely painful PC calluses necessitated oral
pain medication and regional nerve blocks to make treatment
bearable (Leachman et al., 2010).
In light of the limitations of the currently available siRNA
skin delivery technologies, the field would greatly benefit
from the development of patient-friendly technologies or
refinements of existing technologies that allow siRNA to be
efficiently delivered across the stratum corneum and allow
functional uptake by keratinocytes. At a meeting held last
year in Montreal entitled ‘‘Achieving Successful Delivery of
Nucleic Acids to Skin’’ the attendees concluded that effective
siRNA-based therapeutics will likely require a combination of
methodologies that facilitate stratum corneum penetration
and keratinocyte uptake (Kaspar et al., 2009; Gonzalez-
Gonzalez et al., 2010b). Furthermore, a consensus arose that
in order to make rapid progress toward development of
patient-friendly nucleic acid delivery technologies, standar-
dized in vitro and in vivo models are needed as well as
common pools of nucleic acids (including siRNAs) to allow a
comparative ‘‘apples to apples’’ evaluation. To this end, a
National Institutes of Health Grand Opportunities (GO
Delivery!) proposal was recently funded with the aim of (i)
bringing together researchers with expertise in nucleic acid
delivery; (ii) developing reagents, model assay systems and
analysis tools that can be used in a validated and transferable
algorithm for testing delivery of nucleic acids to cells in the
epidermis; and (iii) providing a mechanism to share reagents,
skin models, results, and ideas (Kaspar et al., 2009). This
consortium is beginning to bear fruit as a number of delivery
technologies have been tested (the results of these studies will
be reported elsewhere).
The availability of self-delivery siRNAs that are readily
taken up by skin keratinocytes, coupled with a stratum
corneum penetration strategy (e.g., microneedles or topical
formulations), may result in patient-friendly delivery of
sufficient quantities of inhibitor to result in clinical efficacy.
We have recently reported that dissolvable microneedle
arrays can deliver self-delivery siRNAs and inhibit reporter
gene expression in a transgenic mouse model (Gonzalez-
Gonzalez et al., 2010 b). The ability of these siRNAs to block
expression in a human skin equivalent model, under
conditions in which non-self-delivery siRNAs have little or
no effect, bodes well for use of this class of inhibitors in
patient skin and the future for RNA interference-based skin
therapeutics.
MATERIALS AND METHODS
Design of siRNA
SiRNAs (Accell and non-Accell) were synthesized by Thermo Fisher
Scientific, Dharmacon Products (Lafayette, CO). K6a_513a.12
((Hickerson et al., 2008); also known as TD101 (Leachman et al.,
2010)), EGFP (Hickerson et al., 2008), and CBL3 (Gonzalez-
Gonzalez et al., 2009) siRNA sequences have been previously
reported.
Preparation and maintenance of primary keratinocyte
cell lines
Human PEKp cells were obtained from CELLnTEC Advanced Cell
Systems AG (Bern, Switzerland) and maintained according to the
manufacturer’s instructions. Briefly, cells were thawed and trans-
ferred into CnT-57 medium at 4 103 cells cm2. Once 70–80%
confluent, cells were collected by trypsinization using TrypLE Select
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions and passaged at the same density. PC-10 primary keratinocytes
were isolated as described in Hickerson et al., 2010. PC-799 primary
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keratinocytes (immortalized keratinocytes derived from a PC patient
with a K6a p.Asn171Lys mutation) were isolated from an epidermal
biospy taken at the University of Utah from the thigh of a patient
harboring the K6a p.Asn171Lys mutation (IPCRR patient
no. 799). The study was conducted according to the Declaration
of Helsinki Principles under Western Institutional Review Board
(IRB) approval (Western IRB Study no. 1057496), and participants
gave their written informed consent. All patients were genotyped as
part of the IRB-approved registry maintained by Pachynychia
Congenita Project (http://www.pachyonychia.org, see also Wilson
et al., this issue). The IPCRR no. 799 biopsy was shipped overnight
on ice in Epilife medium (Invitrogen) containing antibiotic/anti-
mycotic (Invitrogen; contains 10,000 units of penicillin, 10,000mg of
streptomycin, and 25 mg of amphotericin B per ml). The biopsy was
incubated in 12ml CnT-57 medium containing 10mgml1 Dispase
II (Roche, Indianapolis, IN) and 2 antibiotic/antimycotic for
15 hours at 4 1C. The epidermis was removed from the dermis and
incubated in a 500ml ‘‘drop’’ of TrypLE Select on a Petri plate for
30minutes at 21 1C. The tissue was disrupted by gentle rubbing on
the surface of the Petri plate. Cells were diluted with at least 2.5
volumes of CnT-57 medium, collected by centrifugation at 160 g
for 5minutes at 21 1C, seeded at 4 104 cells cm2 in CnT-57
medium and expanded as described above.
Preparation of lentiviral expression plasmids
All enzymes were purchased from New England Biolabs (Ipwich,
MA) and all final constructs were verified by DNA sequencing.
Lentiviral expression constructs pCCL-PGK-EGFP (clone 169) and
pCG419 were generously provided by Heini Ilves (Cell Genesys).
The IgK-mar sequence (Yi et al., 1999) from CG419 was inserted
upstream of the central poly-purine tract region of pCCL-PGK-EGFP
to generate pTD147 as follows. pCG419 was digested with HpaI and
XhoI followed by Klenow treatment to generate a 428 bp fragment
containing ‘‘blunt ends’’, which was ligated into HpaI-linearized,
calf intestinal phosphatase-treated pCCL-PGK-EGFP.
The CBL3 siRNA target site was inserted into the 30 untranslated
region of EGFP in pTD147 to generate pTD152. EGFP was PCR
amplified from pTD147 with forward primer 239 (50-CGACCTGC
ATCCCCCGGGTCGCCACCATGGTGAGC) and reverse primer 238
(50-AAGCAGATCTTGTCTTCGTTGGGAGTGAATTAGCCCTTCCAG
TCCCCCCTTTTCTTTTAAAAAGTGGCTAAGATCTACAGCTGCCTTG
TAAGTCATTGGTCTTAAAGCTTAAAGTCGAGGCCGCTGAATTCGT
TTAAACCTTGTAACGATCCACGACGTAAAAATGCGGTACCTTACT
TGTACAGCTCGTCCATG) introducing an XmaI restriction site
(underlined) upstream of the ATG translation start codon (bold) and
the CBL3 target site (italicized) flanked by KpnI, PmeI, and EcoRI
restriction sites (underlined) downstream of the TAA translation stop
codon (bold). The resulting 918-bp PCR fragment was cloned into
pCRII-TOPO vector (Invitrogen), the product of which was digested
with BbsI and BfuAI in the presence of 20 ngml1 duplex DNA
containing the BfuAI restriction site (oligo 240: 50-ACTGATACC
TGCTCGACATGTTCATT and oligo 241: 50-AATGAACATGTCGAGC
AGGTATCAGT) to release the 898-bp fragment containing EGFP and
the CBL3 siRNA target site. This fragment was ligated into BbsI/BfuAI-
digested pTD147.
To generate pTD171, the CBL3 target site was inserted into the 30
untranslated region of tdTOM in pFULT, a lentiviral vector that
expresses Luc2 and tdTOM under the control of the ubiquitin C pro-
moter (Liu et al., 2010). Oligos (oligo-274: 50-GTAGTCTAGATTTTT
ACGTCGTGGATCGTTACAATCTAGAATCG and oligo-275: 50-CGA
TTCTAGATTGTAACGATCCACGACGTAAAAATCTAGACTAC) con-
taining the CBL3 target site (italicized) flanked by XbaI restriction
sites (underlined) were synthesized, annealed, and digested with
XbaI to generate a 26-bp fragment that was inserted into XbaI-
digested pFULT.
Preparation of lentivirus
Human 293T embryonic kidney cells (Invitrogen) were maintained
in DMEM (CAMBREX/BioWhittaker, Walkersville, MD) with 10%
fetal bovine serum (HyClone, Logan, UT), supplemented with 2mM
L-glutamine and 1mM sodium pyruvate (growth media). The day
before transfection, 293T cells were seeded at 5 to 8 106 cells per
10 cm plate resulting in 50–80% cell confluency at the time of
transfection. The medium was replaced with fresh medium
0.5–3hours before transfection. Cells were transfected with 17mg transfer
vector (pTD147, pTD152, or pTD171), 8mg pMDLg/p-RRE (packaging
construct), 3.5mg pRSVrev–rev complementary DNA-expression plasmid
(Dull et al., 1998), and 3.5mg pMD2.G–vesicular stomatitis virus
envelope-expressing construct (Follenzi et al., 2000), using the CalPhos
Mammalian Transfection Kit (BD Biosciences, San Jose, CA) according to
the manufacturer’s protocol. Virus was collected at 24 and 36hours after
transfection and centrifuged for 10minutes at 2,000 r.p.m. to remove
cellular debris. Virus was either stored at 4 1C and used within 48hours
or aliquoted and stored at 80 1C.
Preparation of single- and dual-reporter primary keratinocyte
cell line
Human PEKp cells were transduced by spinoculation (Berkowitz
et al., 2001). Cells (500,000) were seeded 24 hours before
transduction in a T25 flask in CnT-57 medium. Lentivirus
(10ml in DMEM containing 10% fetal bovine serum) was
concentrated by ultracentrifugation in a SW28 rotor at 20,000 g
for 90minutes at 4 1C. The pellet was resuspended in 4ml
ice-cold CnT-57 before transduction. Polybrene (4ml of 8mgml1
phosphate-buffered saline solution) was added and mixed before
addition to the T25 flask. The cap was sealed with parafilm and the
flask was centrifuged in a swinging bucket rotor at 800 g for
20–90minutes at 32 1C. After incubation in a CO2 incubator at 37 1C
for 4–6 hours, the medium was changed and the cells were expanded
in CnT-57 medium as described above. Once 70–80% confluent, the
transduced HPEKp cells (at least 4 106) were trypsinized using
Tryple Select (Invitrogen) according to the manufacturer’s protocols
and resuspended in phosphate-buffered saline containing 0.1%
BSA and antibiotic-antimicotic at 1 106 cellsml1. The suspension
was kept on ice until sorting. Sterile cell sorting was performed
on the basis of EGFPþ fluorescence using a BD FACSAria II
(BD Biosciences) with a 100mm nozzle. EGFP signal was excited
with a 488 nm laser and detected with a 530/30 nm band-pass
emission filter. An initial forward scatter and side scatter gate
was set to include viable homogeneous cells and to exclude debris.
The gated cells exhibiting the top 25% of EGFP expression
were sorted, collected in CnT-57 medium, and plated at 4 103
cells cm2 in a T25 flask. For the dual-reporter HPEKp cell line, once
the EGFP-transduced and sorted cells reached 60–80% confluency, a
second transduction with vTD171 was performed as described
above. These cells were sorted on the basis of tdTOM signal using
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the same 488 nm excitation laser and a 585/42 nm band-pass
emission filter.
Preparation of skin equivalents
Human skin equivalents were prepared using the three-dimensional
epidermal culture system (CELLnTEC) following the manufacture’s
instructions. HPEKp cells were maintained in CnT-57 medium and
seeded (200,000 cells in 400ml) in 12-mm inserts lined with a 0.4mm
porous membrane (Millipore, Billerica, MA). The inserts were main-
tained in a 6-cm plate containing 10.5ml CnT-57 medium. After 2–3
days, the CnT-57 medium in both the insert and the plate was replaced
with differentiation medium (CnT-02-3DP); this is referred to as ‘‘day 0’’.
After 15–16hours, the medium in the insert was removed, and the
medium in the plate was replaced with 3ml fresh differentiation
medium to generate an air-liquid interface.
Treatment of three-dimensional and monolayer epidermal
cultures with siRNAs
Human PEKp cells (20,000 cells in each well of a 24-well plate in
CnT-57 medium) were seeded 24 hours before treatment. Three-
dimensional epidermal cultures were seeded 1–2 weeks before
treatment. siRNA was added to a final concentration of 2mM (optimal
concentration determined by dose–response studies in primary
human keratinocytes, data not shown; this concentration is also
consistent with the manufacture’s (Dharmacon) recommendations)
directly to the medium in the lower chamber, leaving the surface
of the epidermal equivalent dry. EGFP levels were measured by
fluorescence imaging in the IVIS Lumina II in vivo imaging system
(Caliper Life Sciences, Hopkinton, MA) with the 465 nm excitation
and GFP emission filters. Messenger RNA knockdown was measured
by quantitative reverse transcription PCR as described in (Hickerson
et al., this issue) by lysis in Qiazol (Qiagen, Valencia, CA) and
purified using the RNeasy kit (Qiagen), which includes an on-
column DNase digestion. Total RNA was reverse transcribed from
random hexamer primers using the First Strand Synthesis Kit
containing Superscript III (Invitrogen). Target gene knockdown was
analyzed using a custom TaqMan gene expression assay for K6a
p.Asn171Lys mutant and wild-type mRNA (Hickerson et al., 2010)
and an inventoried GAPDH TaqMan gene expression assay
(Hs_99999905_m1) as the reference gene (Applied Biosystems,
Foster City, CA).
Immunohistochemistry
Immunohistochemical staining was performed using K5-specific (Santa
Cruz Biotech, Santa Cruz, CA) and K10-specific (Lab Vision, Freemont,
CA) antibodies. Skin equivalents were frozen in optimal cutting
temperature compound medium and sectioned (10mm). Sections were
fixed in acetone at 20 1C for 15minutes, dried and blocked with 10%
heat-inactivated goat serum, 1% BSA, 0.025% Triton X-100 in
phosphate-buffered saline for 1hour at 21 1C and incubated overnight
in a 1:500 dilution of the primary antibody in the same solution used for
blocking. Rinsed slides were incubated for 1hour with the appropriate
Alexa-546-conjugated secondary antibody (1:2,000 dilution; Invitro-
gen) and mounted with Hydromount (National Diagnostics, Atlanta,
GA) containing 40,6-diamidino-2-phenylindole (DAPI, 1mgml1) to
counterstain nuclei. Sections were imaged using a Zeiss Axio Observer
Inverted Fluorescence Microscope equipped with DsRed and DAPI
filter sets (Carl Zeiss Microimaging, Thornwood, NY).
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